Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial.

Santagostino E, Lalezari S, Reding MT, Ducore J, Ng HJ, Poulsen LH, Michaels LA, Linardi CCG.

Thromb Res. 2019 Nov;183:13-19. doi: 10.1016/j.thromres.2019.08.023. Epub 2019 Aug 26.

2.

A novel approach to immune tolerance induction in haemophilia A with factor VIII inhibitor.

Thornburg CD, Ducore J.

Haemophilia. 2019 Jan;25(1):e48-e50. doi: 10.1111/hae.13646. Epub 2018 Nov 23. No abstract available.

PMID:
30468284
3.

Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.

George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA.

N Engl J Med. 2017 Dec 7;377(23):2215-2227. doi: 10.1056/NEJMoa1708538.

4.

Primary Renal Lymphoma Presenting as End-Stage Renal Disease.

Butani L, Ducore J.

Case Rep Med. 2017;2017:9210648. doi: 10.1155/2017/9210648. Epub 2017 Oct 2.

5.

Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.

Ducore J, Lawrence JB, Simpson M, Boggio L, Bellon A, Burggraaf J, Stevens J, Moerland M, Frieling J, Reijers J, Wang M.

Haemophilia. 2017 Nov;23(6):844-851. doi: 10.1111/hae.13357. Epub 2017 Oct 5.

PMID:
28984010
6.

Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.

Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ.

Haemophilia. 2018 Mar;24(2):211-220. doi: 10.1111/hae.13320. Epub 2017 Aug 16.

PMID:
28815880
7.

PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.

Wang M, Lawrence JB, Quon DV, Ducore J, Simpson ML, Boggio LN, Mitchell IS, Yuan G, Alexander WA, Schved JF.

Haemophilia. 2017 Nov;23(6):832-843. doi: 10.1111/hae.13301. Epub 2017 Aug 3.

PMID:
28776894
8.

Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery.

Buckner TW, Leavitt AD, Ragni M, Kempton CL, Eyster ME, Cuker A, Lentz SR, Ducore J, Leissinger C, Wang M, Key NS.

Thromb Haemost. 2016 Jul 4;116(1):42-9. doi: 10.1160/TH15-10-0802. Epub 2016 Mar 24.

PMID:
27009484
9.

End-Stage Renal Disease From Cast Nephropathy in a Teenager With Neuroendocrine Carcinoma.

Butani L, Ducore J.

J Pediatr Hematol Oncol. 2016 Jul;38(5):e177-9. doi: 10.1097/MPH.0000000000000556.

PMID:
26989910
10.

Dust metal loadings and the risk of childhood acute lymphoblastic leukemia.

Whitehead TP, Ward MH, Colt JS, Dahl G, Ducore J, Reinier K, Gunier RB, Katharine Hammond S, Rappaport SM, Metayer C.

J Expo Sci Environ Epidemiol. 2015 Nov-Dec;25(6):593-8. doi: 10.1038/jes.2015.9. Epub 2015 Mar 4.

11.

Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.

Ducore JM, Miguelino MG, Powell JS.

Expert Rev Hematol. 2014 Oct;7(5):559-71. doi: 10.1586/17474086.2014.951322. Epub 2014 Aug 21.

PMID:
25142322
12.

WARM N COLD: malignant and benign renal tumors in children.

Sanchez TR, Ducore J, Balagtas J, Molloy C, Wootton-Gorges SL.

Emerg Radiol. 2014 Jun;21(3):261-9. doi: 10.1007/s10140-014-1202-8. Epub 2014 Feb 26. Review.

PMID:
24570120
13.

Tobacco smoke exposure and the risk of childhood acute lymphoblastic and myeloid leukemias by cytogenetic subtype.

Metayer C, Zhang L, Wiemels JL, Bartley K, Schiffman J, Ma X, Aldrich MC, Chang JS, Selvin S, Fu CH, Ducore J, Smith MT, Buffler PA.

Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1600-11. doi: 10.1158/1055-9965.EPI-13-0350. Epub 2013 Jul 12.

14.

Children and adolescents with ALL are taller than expected at diagnosis.

Huang T, Ducore JM.

J Pediatr Hematol Oncol. 2014 Jan;36(1):16-21. doi: 10.1097/MPH.0b013e31829bcb10.

PMID:
23799523
15.

Oral or parenteral administration of curcumin does not prevent the growth of high-risk t(4;11) acute lymphoblastic leukemia cells engrafted into a NOD/SCID mouse model.

Zunino SJ, Storms DH, Newman JW, Pedersen TL, Keen CL, Ducore JM.

Int J Oncol. 2013 Feb;42(2):741-8. doi: 10.3892/ijo.2012.1734. Epub 2012 Dec 12.

16.

Dietary resveratrol does not delay engraftment, sensitize to vincristine or inhibit growth of high-risk acute lymphoblastic leukemia cells in NOD/SCID mice.

Zunino SJ, Storms DH, Newman JW, Pedersen TL, Keen CL, Ducore JM.

Int J Oncol. 2012 Dec;41(6):2207-12. doi: 10.3892/ijo.2012.1650. Epub 2012 Oct 4.

17.

Resveratrol given intraperitoneally does not inhibit the growth of high-risk t(4;11) acute lymphoblastic leukemia cells in a NOD/SCID mouse model.

Zunino SJ, Storms DH, Newman JW, Pedersen TL, Keen CL, Ducore JM.

Int J Oncol. 2012 Apr;40(4):1277-84. doi: 10.3892/ijo.2011.1316. Epub 2011 Dec 22.

18.

Thrombotic thrombocytopenic purpura in a child with systemic lupus erythematosus.

Thampi S, Salmi D, Imashuku S, Ducore J, Satake N.

J Pediatr Hematol Oncol. 2011 Apr;33(3):221-3. doi: 10.1097/MPH.0b013e318208425d.

PMID:
21336165
19.

Diagnostic X-rays and risk of childhood leukaemia.

Bartley K, Metayer C, Selvin S, Ducore J, Buffler P.

Int J Epidemiol. 2010 Dec;39(6):1628-37. doi: 10.1093/ije/dyq162. Epub 2010 Oct 1.

21.

Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11).

Zunino SJ, Storms DH, Ducore JM.

Cancer Lett. 2010 Oct 1;296(1):49-54. doi: 10.1016/j.canlet.2010.03.017. Epub 2010 Apr 9.

22.

Risk factors for the development of obesity in children surviving ALL and NHL.

Gofman I, Ducore J.

J Pediatr Hematol Oncol. 2009 Feb;31(2):101-7. doi: 10.1097/MPH.0b013e31818c0120.

PMID:
19194192
23.

Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells.

Zunino SJ, Ducore JM, Storms DH.

Cancer Lett. 2007 Aug 28;254(1):119-27. Epub 2007 Apr 30.

PMID:
17470383
24.

Breastfeeding patterns and risk of childhood acute lymphoblastic leukaemia.

Kwan ML, Buffler PA, Wiemels JL, Metayer C, Selvin S, Ducore JM, Block G.

Br J Cancer. 2005 Aug 8;93(3):379-84.

25.

Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.

Winter SS, Holdsworth MT, Devidas M, Raisch DW, Chauvenet A, Ravindranath Y, Ducore JM, Amylon MD.

Pediatr Blood Cancer. 2006 Feb;46(2):179-86.

PMID:
16007607
26.

Rhabdomyoblastic pulmonary lesions in a patient with Wilms tumor: choristomas or metastases?

Zwerdling T, Ducore J, Taylor D, West DC, Konia T.

Pediatr Blood Cancer. 2006 Mar;46(3):381-4.

PMID:
15926167
27.

Cancer Occurrence in Southeast Asian Children in California.

Ducore JM, Parikh-Patel A, Gold EB.

J Pediatr Hematol Oncol. 2004 Oct;26(10):613-618.

PMID:
27811600
28.

Cancer occurrence in Southeast Asian children in California.

Ducore JM, Parikh-Patel A, Gold EB.

J Pediatr Hematol Oncol. 2004 Oct;26(10):613-8.

PMID:
15454830
29.

Surveillance neuroimaging to detect relapse in childhood brain tumors: a Pediatric Oncology Group study.

Minn AY, Pollock BH, Garzarella L, Dahl GV, Kun LE, Ducore JM, Shibata A, Kepner J, Fisher PG.

J Clin Oncol. 2001 Nov 1;19(21):4135-40.

PMID:
11689581
30.

Paraparesis, hypermanganesaemia, and polycythaemia: a novel presentation of cirrhosis.

Gospe SM Jr, Caruso RD, Clegg MS, Keen CL, Pimstone NR, Ducore JM, Gettner SS, Kreutzer RA.

Arch Dis Child. 2000 Nov;83(5):439-42.

31.

Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study.

Mulne AF, Ducore JM, Elterman RD, Friedman HS, Krischer JP, Kun LE, Shuster JJ, Kadota RP.

J Pediatr Hematol Oncol. 2000 Jan-Feb;22(1):41-4.

PMID:
10695820
32.

Bone marrow transplant in thalassemia. A role for radiation?

Lee YS, Kristovich KM, Ducore JM, Vichinsky E, Crouse VL, Glader BE, Amylon MD.

Ann N Y Acad Sci. 1998 Jun 30;850:503-5. No abstract available.

PMID:
9668596
33.

Hydrogen peroxide induces DNA single strand breaks in respiratory epithelial cells.

McDonald RJ, Pan LC, St George JA, Hyde DM, Ducore JM.

Inflammation. 1993 Dec;17(6):715-22.

PMID:
8112830
34.

A DNA crosslinking drug alters synthesis of several low molecular weight proteins in human lymphoma cells.

Widstrom RL, Ducore JM.

Biochem Biophys Res Commun. 1991 Apr 30;176(2):717-21.

PMID:
2025284
35.

High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study.

Ravindranath Y, Steuber CP, Krischer J, Civin CI, Ducore J, Vega R, Pitel P, Inoue S, Bleher E, Sexauer C, et al.

J Clin Oncol. 1991 Apr;9(4):572-80.

PMID:
2066754
36.

Bone pain as an initial symptom of childhood acute lymphoblastic leukemia: association with nearly normal hematologic indexes.

Jonsson OG, Sartain P, Ducore JM, Buchanan GR.

J Pediatr. 1990 Aug;117(2 Pt 1):233-7.

PMID:
2380822
38.

DNA-protein crosslinking in normal and solar UV-sensitive ICR 2A frog cell lines exposed to solar UV-radiation.

Rosenstein BS, Lai LW, Ducore JM, Rosenstein RB.

Mutat Res. 1989 May;217(3):219-26.

PMID:
2716758
39.
40.

Cytotoxicity and DNA damage caused by the azoxy metabolites of procarbazine in L1210 tumor cells.

Erikson JM, Tweedie DJ, Ducore JM, Prough RA.

Cancer Res. 1989 Jan 1;49(1):127-33.

42.

DNA-protein crosslinking in normal human skin fibroblasts exposed to solar ultraviolet wavelengths.

Lai LW, Ducore JM, Rosenstein BS.

Photochem Photobiol. 1987 Jul;46(1):143-6.

PMID:
3615631
48.
50.

Supplemental Content

Loading ...
Support Center